METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES

(19)

(11)

EP 3 873 524 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	09.04.2025 Bulletin 2025/15

(45)	Mention of the grant of the patent:
	26.02.2025 Bulletin 2025/09

(21)	Application number: 19878291.4

(22)	Date of filing: 30.10.2019

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
A61P 35/00^(2006.01)

A61K 51/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/5513; A61P 35/02; A61K 47/6849; A61K 9/0019; C07K 16/2866; A61K 2039/505; A61K 2039/545; C07K 2317/92; A61K 47/68035

(86)	International application number:
	PCT/US2019/058824

(87)	International publication number:
	WO 2020/092533 (07.05.2020 Gazette 2020/19)

(54)	METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES BEHANDLUNGSVERFAHREN UNTER VERWENDUNG VON ANTI-CD123-IMMUNOKONJUGATEN PROCÉDÉS DE TRAITEMENT FAISANT APPEL À DES IMMUNOCONJUGUÉS ANTI-CD123

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

30.10.2018 US 201862752832 P
12.06.2019 US 201962860565 P
31.07.2019 US 201962881137 P

(43)	Date of publication of application:
	08.09.2021 Bulletin 2021/36

(60)	Divisional application:
	25159743.1

(73)	Proprietor: ImmunoGen, Inc.
	North Chicago, IL 60064 (US)

(72)	Inventors:
	ZWEIDLER-MCKAY, Patrick Lincoln, Massachusetts 01773 (US) CULM-MERDEK, Kerry Natick, Massachusetts 01760 (US) SLOSS, Callum Wakefield, Massachusetts 01880 (US) ROMANELLI, Angela Manchester-by-the-Sea, Massachusetts 01944 (US)

(74)	Representative: Simmons & Simmons LLP (Munich) et al
	Lehel Carré Gewürzmühlstraße 11 80538 Munich 80538 Munich (DE)

(56)

References cited: :

WO-A2-2018/098258
US-A1- 2017 152 321

US-A1- 2017 152 321
US-A1- 2018 169 261

TOLCHER A.W.: "Antibody drug conjugates: lessons from 20 years of clinical experience", ANNALS OF ONCOLOGY, vol. 27, no. 12, 1 December 2016 (2016-12-01), pages 2168 - 2172, XP093147201, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw424
DAVER NAVAL G ET AL: "A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 27, XP086593652, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-112955
TOLCHER A.W.: "Antibody drug conjugates: lessons from 20 years of clinical experience", ANNALS OF ONCOLOGY, vol. 27, no. 12, 1 December 2016 (2016-12-01), pages 2168 - 2172, XP093147201, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw424
DAVER NAVAL G ET AL: "A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 27, XP086593652, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-112955
TOLCHER A.W.: "Antibody drug conjugates: lessons from 20 years of clinical experience", ANNALS OF ONCOLOGY, vol. 27, no. 12, 1 December 2016 (2016-12-01), pages 2168 - 2172, XP093147201, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw424
DAVER NAVAL G ET AL: "A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 27, XP086593652, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-112955


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).